Curing pediatric cancer is such a big and complex challenge, it’s unrealistic to think that any one pediatric center can get the job done alone. By working together in a coordinated way, we can accomplish more, with greater benefits, at lower costs.
As a member, your institution will be able to participate in the CureWorks pipeline and provide innovative immunotherapies directly to your patients. This allows you to treat more patients locally, while redefining the standard of care globally. Members benefit from access to an array of technologies, data, and expertise, including clinical trial coordination and manufacturing of individual treatments.
Unprecedented CAR T experience and technologies, including process expertise to accelerate translation from “bench to bedside.”
Members leverage individual and collective expertise around CAR T-cell therapies, clinical trials management, grants, regulatory affairs, and manufacturing.
Members gain access to GMP facility to produce treatments for their patients at a reduced level of capital investment.
Management of external communications with constituent communities, government agencies, media, and other stakeholders.
Expanded access to diverse participant pool, streamlined enrollment process, multi-site trial strategy, and regulatory agency expertise.
We are building an organization and a pipeline that will continuously push the bounds of scientific discovery in pursuit of cures. We see a world where there is no chemo, no radiation, and finally, no pediatric cancer.
29,000
Square feet of manufacturing space (in 2020)
500
GMP grade engineered cell products per year (in 2020)
11
Trials Currently in pipeline
We are looking for institutions that share our commitment to expanding access to these promising cures for children. To learn more about becoming a participating institution, please contact us at info@cureworks.org
Learn more about our science and progress.
CD19-specific chimeric antigen receptor (CAR)–expressing autologous T cells administered after lymphodepleting chemotherapy can induce clinical remissions in B-lineage malignancies, including refractory pediatric acute lymphoblastic leukemia (ALL), irrespective of disease burden or anatomic dissemination.